Karyopharm Therapeutics Q2 Loss Wider Than Expected, Revenue Misses Estimates

Karyopharm Therapeutics (KPTI) reported a Q2 loss of $4.32 per share, missing the Zacks Consensus Estimate of a loss of $3.8. Revenues were $37.93 million, missing the consensus estimate by 5.37%. The company has underperformed the market this year, but the earnings outlook is mixed, with a Zacks Rank of #3 (Hold). The current consensus EPS estimate is -$3.58 on $39.87 million in revenues for the coming quarter and -$12.57 on $149.93 million in revenues for the current fiscal year.

Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company, reported its second quarter financial results on August 11, 2025, revealing a net loss of $37.3 million. The loss per share was $4.32, falling short of the Zacks Investment Research consensus estimate of $3.80 per share [1]. The company's revenue for the period was $37.9 million, which also missed the Street's forecast of $40.1 million [1].

The Newton, Massachusetts-based company attributed the loss to increased research and development (R&D) expenses and lower-than-expected sales of its XPOVIO® (selinexor) product. Despite the loss, Karyopharm reaffirmed its full-year 2025 total revenue guidance of $140 million to $155 million and updated its U.S. XPOVIO net product revenue guidance to $110 million to $120 million [2].

In its Q2 2025 highlights, Karyopharm noted that the Phase 3 SENTRY trial in myelofibrosis is nearing full enrollment, with new patient screening expected to close this week. The company anticipates top-line results from this pivotal trial in March 2026. Additionally, the company reported that its XPOVIO commercial performance was consistent with the previous quarter, with U.S. net product revenue at $29.7 million, a 6% increase compared to the second quarter of 2024 [2].

Looking ahead, Karyopharm expects to report top-line data from the Phase 3 XPORT-MM-031 trial in multiple myeloma in the first half of 2026 and from the Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026. The company is also exploring financing transactions and strategic alternatives to extend its cash runway and maximize value.

The company's stock has underperformed the market this year, but the earnings outlook is mixed, with a Zacks Rank of #3 (Hold). The current consensus EPS estimate for the coming quarter is -$3.58 on $39.87 million in revenues, and for the current fiscal year, it is -$12.57 on $149.93 million in revenues [1].

References:

[1] https://www.marketscreener.com/news/karyopharm-therapeutics-q2-earnings-snapshot-ce7c5ed3d880f527
[2] https://www.prnewswire.com/news-releases/karyopharm-reports-second-quarter-2025-financial-results-and-highlights-recent-company-progress-302525657.html